Supernus Pharmaceuticals Reports Third Quarter 2026 Financial Results

Supernus Pharmaceuticals reported record third-quarter 2026 revenue of $226.8 million, up 18% year over year. Revenue from its four growth products—Qelbree, GOCOVRI, ZURZUVAE and ONAPGO—rose 29% to $192.2 million. The company said its merger with Indivior remains on track to close November 2, 2026, positioning the combined company as a CNS-focused biopharmaceutical leader.